- Hazelwood MO, US - Bedminster NJ, US Carmen Mak - Hampton NJ, US Nagaraju Poola - Belle Mead NJ, US Regis Vilchez - Chicago IL, US Aniruddha Potnis - King of Prussia PA, US Susan VanMeter - Ashburn VA, US Jan Stange - San Diego CA, US
International Classification:
A61K 31/198 A61P 1/16
Abstract:
Embodiments of the present disclosure relate to doses of ornithine phenylacetate for treating or ameliorating hyperammonemia and the methods of administrating the same in a patient with a chronic liver disease, for example, cirrhosis. In some embodiments, the patient also has hepatic encephalopathy as a complication of the liver disease.
Vital Therapies, Inc.
Chief Medical Officer
Janstange
Business Angel Engagements
Octapharma Usa Inc Nov 2012 - Nov 2012
Clinical Advisory Board
Nxstage Medical, Inc. Oct 2012 - Oct 2012
Critical Care Advisory Board
Arbios Systems Jan 2006 - Dec 2007
Chairman of Data Safety Monitoring Board
Education:
Uc San Diego 2000 - 2004
Universität Rostock 1985 - 2000
Doctorates, Masters, Doctor of Philosophy, Doctor of Medicine, Master of Education, Medicine
Universität Rostock 1990 - 1991
Master of Education, Masters
Skills:
Life Sciences Medical Devices Pharmaceutical Industry Management Clinical Trials Clinical Research Research Leadership Strategic Planning Biotechnology Clinical Development Medicine Healthcare